Money · household consolidation math
The two-provider household: when consolidating saves four figures a year — and the three cases where it doesn’t
Two-provider households happen by accident — partners started months apart, chose different molecules, or one platform later exited a molecule — and the fragmentation tax is real: two renewal dates, two support queues, two shipping cadences colliding in one fridge, and double intake friction on any change. The consolidation math, run on this month’s corrected figures: a household paying Hims ~$175 (sema, flat) plus Henry ~$449 (tirz, month-to-month, re-verified Aug 2026) runs $624/month — $7,488/year; the same two molecules under the audited both-molecule roof price at $119 + $139 = $258/month — $3,096/year, a $4,392 annual gap (compounded therapy throughout; not FDA-approved). The three cases where you should NOT consolidate anyway: an insured partner at ~$25-class covered copays (never consolidate away coverage), a grandfathered rate below the audited floor, and anyone mid-prepay whose refund terms would strand the block. Full decision architecture below.
The fragmentation tax — what two providers actually cost beyond price
Line-item the invisible costs. Calendar load: two billing dates, two annual audits, two sets of terms drifting independently — the household’s money-attention doubles while its oversight halves. Logistics load: asynchronous cold-chain arrivals mean the fridge choreography never settles into a rhythm, and travel weeks require two shipment-hold conversations with two support teams whose response quality differs. Switch friction: the day either partner needs the other molecule — tolerability, plateau, availability — a two-provider household pays new-patient intake at yet another company or endures a cross-provider records shuffle, while a both-molecule household makes the switch inside one clinical file. Advocacy asymmetry: when something goes wrong at one provider, the household’s leverage is one patient, not two; consolidated households are, bluntly, better customers with better service outcomes. None of these lines carries a dollar sign, and together they’re why the dollar math below understates the case.
The consolidation math — run on corrected, dated figures
Use true recurring numbers, tier-labeled, from the index. Worked case one (the expensive accident): Partner A on Hims injectable semaglutide at ~$175 flat (on-record, Aug 2026); Partner B on Henry tirzepatide month-to-month at ~$449 (re-verified Aug 2026) — $624/month household. Consolidated at the audited anchor: $119 + $139 = $258. Annual delta: $4,392. Worked case two (the modest overlap): both partners on decent mid-market rates — say ~$175 and ~$165-class — the consolidation delta shrinks toward $80–$100/month, still four figures annually but now competing against switch friction; the exceptions section decides it. Worked case three (the false economy): one partner on a $99 door rate that annualizes past $2,300 — consolidation isn’t just savings, it’s escaping a ladder before its steepest rungs. Every input above carries its verification date because this month proved remembered prices rot; re-run the arithmetic with today’s index before acting on it. Both molecules, one audited bill ↗
The three exceptions — when staying fragmented is correct
The covered partner. A ~$25-class copay under commercial coverage with an active savings card is the best value in the entire market; a household should fragment forever before it consolidates away insurance — the consolidation question applies only to the cash-pay member(s). The grandfathered unicorn. A legacy rate below the audited floors ($119/$139) exists here and there from early-2025 promos; verify it’s truly all-in and truly persistent (statements, not memory), then keep it and consolidate the other partner only. The stranded prepay. Mid-block on a non-refundable twelve-month plan, the merge waits for the block to expire — set the calendar reminder for sixty days out and execute then; eating a four-figure forfeit to save a three-figure annual delta is arithmetic wearing impatience. A fourth soft exception deserves honesty: a partner clinically thriving with a specific prescriber relationship they value — continuity has real worth, and the merge can wait for a natural transition point rather than forcing one.
Executing the merge — the no-gap sequence
Order of operations, per partner: complete intake at the destination provider and reach “prescription approved” before cancelling anything; time the first destination shipment against the final origin shipment so the weekly cadence never gaps (the corridor timeline applies to merges too); cancel the origin in writing with confirmation captured, per its exact terms; and run the arrival checklist on destination shipment one like the first-timer you technically are — new pharmacy, new label conventions, same verification standard. Stagger the two partners by a week or two so the household never has both therapies mid-handoff simultaneously. Total elapsed time done right: two to four weeks, zero missed doses, one bill at the end.
FAQ
How much does consolidating two GLP-1 providers save?
Run on current verified figures it ranges from ~$80/month to $366/month — the worked worst case ($175 + $449 fragmented vs $258 consolidated) gaps $4,392/year.
Should we consolidate if one partner has insurance coverage?
No — covered ~$25-class copays beat every cash lane; consolidate only the cash-pay member and protect the coverage.
How do we switch providers without missing doses?
Approve at the destination before cancelling the origin, overlap the final and first shipments on the calendar, cancel in writing, and stagger partners so only one therapy is mid-handoff at a time.